The CSL Ltd (ASX: CSL) share price is in focus after the company reported a 5% revenue increase to US$15.6 billion and a 17% lift in NPAT for FY25.
Image source: Getty Images
What did CSL Limited report?
- Revenue rose 5% to US$15.6 billion
- Net profit after tax (NPAT) jumped 17% to US$3.0 billion
- Underlying NPATA up 14% to US$3.3 billion
- Earnings before interest, tax, depreciation and amortisation (EBITDA) grew 11% to US$5.3 billion
- Final dividend of US$1.62 per share, up 12%
- Cash flow from operations increased by 29% to US$3.6 billion
What else happened in FY25?
CSL Behring delivered strong performance, particularly in plasma therapies, with immunoglobulin and haemophilia products driving growth. CSL Vifor posted an 8% revenue increase, supported by momentum in iron and nephrology portfolios. CSL Seqirus maintained its position as a global leader in influenza vaccines, securing major avian flu contracts despite lower immunisation rates in the US.
Major strategic initiatives were announced to drive future growth and efficiency, including plans to demerge CSL Seqirus as a separate ASX-listed entity in FY26. CSL also intends to restart a multi-year on-market share buyback from FY26, beginning with an initial A$750 million in the first year.
What did CSL management say?
Commenting on the result, CSL's Chief Executive Officer and Managing Director Dr. Paul McKenzie said:
I am pleased to report another on-target result for the 2025 financial year, led by CSL Behring and continued strong demand for our life-saving plasma therapies… The long-term outlook for CSL's therapies and vaccines remains distinctly positive, with multiple growth opportunities driven by increasing patient demand, unique competitive positions, and scalable platforms.
What's next for CSL?
Looking ahead to FY26, CSL expects group revenue growth of around 4–5%, with continued solid demand for CSL Behring products and the launch of new therapies. The company anticipates annual pre-tax cost savings over $500 million by FY28, with savings to be reinvested into priority growth areas.
CSL confirmed the planned demerger of Seqirus and the recommencement of its share buyback program. Management remains focused on simplifying operations, enhancing R&D productivity, and driving sustainable, profitable growth.
CSL share price snapshot
Over the past year, CSL shares have underperformed the S&P/ASX 200 Index (ASX: XJO), declining 12% compared to a 12% rise for the ASX 200 Index. Investors will be watching closely as transformation plans unfold.
